RATIONALE: Accumulating evidence suggests that the primary symptoms of schizophrenia may be associated with altered central glutamate transmission. LY2140023 monohydrate is the methionine prodrug of the selective mGlu(2/3) receptor agonist LY404039 and is currently being assessed for the treatment of schizophrenia. OBJECTIVE: The objective of this study was to evaluate the central pharmacological activity of LY2140023 monohydrate in preclinical and clinical studies. METHODS: Effects on neurotransmitter/metabolite concentrations were assessed in male rats following single oral doses of LY2140023 monohydrate (microdiasylates from the prefrontal cortex), single intraperitoneal injection of LY404039 [cerebrospinal fluid (CSF)], or LY2140023 monohydrate dosed once daily for 7 days (CSF). A clinical study in 16 healthy subjects assessed the effects of LY2140023 monohydrate 40 mg orally twice daily for 14 days in lumbar CSF. RESULTS:Rat studies: Acute dosing with LY2140023 monohydrate resulted in significant dose-dependent increases in extracellular concentrations of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), but not 5-hydroxyindoleacetic acid (5-HIAA), in the prefrontal cortex. LY2140023 monohydrate dosing for 7 days elevated the concentrations of HVA in CSF, while acutely dosed LY404039 increased the concentrations of DOPAC, HVA, and methoxy-hydroxyphenylglycol (MHPG), but not 5-HIAA. Clinical study: Significant increases were seen for DOPAC, HVA, 5-HIAA, and MHPG in the CSF of subjects receiving LY2140023 monohydrate, but not placebo. CONCLUSIONS:LY2140023 monohydrate and/or LY404039 dosing potently affected dopamine turnover and also significantly affected serotonin turnover in the human and rat central nervous systems. The measurement of biogenic amine metabolites such as DOPAC and HVA may serve as useful biomarkers of LY2140023 monohydrate and/or LY404039 central pharmacodynamic activity.
RCT Entities:
RATIONALE: Accumulating evidence suggests that the primary symptoms of schizophrenia may be associated with altered central glutamate transmission. LY2140023 monohydrate is the methionine prodrug of the selective mGlu(2/3) receptor agonist LY404039 and is currently being assessed for the treatment of schizophrenia. OBJECTIVE: The objective of this study was to evaluate the central pharmacological activity of LY2140023 monohydrate in preclinical and clinical studies. METHODS: Effects on neurotransmitter/metabolite concentrations were assessed in male rats following single oral doses of LY2140023 monohydrate (microdiasylates from the prefrontal cortex), single intraperitoneal injection of LY404039 [cerebrospinal fluid (CSF)], or LY2140023 monohydrate dosed once daily for 7 days (CSF). A clinical study in 16 healthy subjects assessed the effects of LY2140023 monohydrate 40 mg orally twice daily for 14 days in lumbar CSF. RESULTS:Rat studies: Acute dosing with LY2140023 monohydrate resulted in significant dose-dependent increases in extracellular concentrations of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), but not 5-hydroxyindoleacetic acid (5-HIAA), in the prefrontal cortex. LY2140023 monohydrate dosing for 7 days elevated the concentrations of HVA in CSF, while acutely dosed LY404039 increased the concentrations of DOPAC, HVA, and methoxy-hydroxyphenylglycol (MHPG), but not 5-HIAA. Clinical study: Significant increases were seen for DOPAC, HVA, 5-HIAA, and MHPG in the CSF of subjects receiving LY2140023 monohydrate, but not placebo. CONCLUSIONS:LY2140023 monohydrate and/or LY404039 dosing potently affected dopamine turnover and also significantly affected serotonin turnover in the human and rat central nervous systems. The measurement of biogenic amine metabolites such as DOPAC and HVA may serve as useful biomarkers of LY2140023 monohydrate and/or LY404039 central pharmacodynamic activity.
Authors: A Bond; N M Jones; C A Hicks; G M Whiffin; M A Ward; M F O'Neill; A E Kingston; J A Monn; P L Ornstein; D D Schoepp; D Lodge; M J O'Neill Journal: J Pharmacol Exp Ther Date: 2000-09 Impact factor: 4.030
Authors: Sandeep T Patil; Richard E Higgs; John E Brandt; Michael D Knierman; Valentina Gelfanova; Jon P Butler; Anncatherine M Downing; Jill Dorocke; Robert A Dean; William Z Potter; David Michelson; Alan X Pan; Stanford S Jhee; John E Hale Journal: J Proteome Res Date: 2007-01-23 Impact factor: 4.466
Authors: James A Monn; Steven M Massey; Matthew J Valli; Steven S Henry; Gregory A Stephenson; Mark Bures; Marc Hérin; John Catlow; Deborah Giera; Rebecca A Wright; Bryan G Johnson; Sherri L Andis; Ann Kingston; Darryle D Schoepp Journal: J Med Chem Date: 2007-01-25 Impact factor: 7.446
Authors: V Bruno; G Battaglia; A Copani; M D'Onofrio; P Di Iorio; A De Blasi; D Melchiorri; P J Flor; F Nicoletti Journal: J Cereb Blood Flow Metab Date: 2001-09 Impact factor: 6.200
Authors: Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp Journal: Nat Med Date: 2007-09-02 Impact factor: 53.440
Authors: Eduardo Dunayevich; Janelle Erickson; Louise Levine; Ronald Landbloom; Darryle D Schoepp; Gary D Tollefson Journal: Neuropsychopharmacology Date: 2007-08-22 Impact factor: 7.853
Authors: Linda M Rorick-Kehn; Bryan G Johnson; Karen M Knitowski; Craig R Salhoff; Jeffrey M Witkin; Kenneth W Perry; Kelly I Griffey; Joseph P Tizzano; James A Monn; David L McKinzie; Darryle D Schoepp Journal: Psychopharmacology (Berl) Date: 2007-03-24 Impact factor: 4.415
Authors: Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange Journal: Pharm Res Date: 2018-02-15 Impact factor: 4.200